A study analyzing Medicare claims found that biopsies accounted for 43.1% of $38.3 million in diagnostic costs for patients with ultimately negative lung cancer diagnoses. Lung biopsies were also the most expensive test, with a median cost of $3,784 and an average cost including complications of $37,745.
Research shows that primary care providers who know guideline recommendations for low-dose computed tomography (LDCT) screening are more likely to order LDCT for high-risk individuals. This knowledge gap is highlighted by a survey of over 200 primary care providers, which found that 48% knew three or more guideline components.
Research reveals that minimally invasive adenocarcinoma (MIA) and adenocarcinoma in-situ (AIS) lung cancer patients have comparable five-year disease-free and overall survival rates of 97.7%. This finding suggests that tumor sub-classification may not provide additional prognostic information for patients with tumors ≤3 cm in size.
Analysis of over 600 small cell lung cancer and neuroendocrine tumors identified common molecular markers, including EGFR amplification, that could reveal new therapeutic targets. The study found notable differences in biomarker expression between SCLC and NET tumors.
A study published in Practical Radiation Oncology evaluated the use of image-guided radiation therapy (IGRT) in treating pediatric cancers. The results show that IGRT is commonly used to improve localization and precision in radiation delivery, particularly for tumors near sensitive structures or organs.
The University of Hawai`i Cancer Center has received a $3.5 million NCORP grant to improve cancer care and prevention among minority and underserved populations in Hawaii. The grant will fund clinical trials and research aimed at reducing cancer disparities and enhancing patient outcomes.
A study published in Journal of Clinical Oncology found that the 2005 Medicare law had no significant impact on reducing chemotherapy drug costs, contradicting economists' expectations. Instead, cancer care costs skyrocketed during the decade after the law passed.
A survey of 80 female Greek oncologists found that women are under-represented in leadership positions, with team leaders being men in 82% of cases. The European Society for Medical Oncology launches a new initiative to promote the exchange of ideas among female oncologists and support women with cancer.
A survey of 895 doctors in Europe, South America, and Asia revealed that over three-quarters of oncology specialists believe their patients are not well-informed about treatment options. The majority (90%) use biomarker testing to choose treatments, but many identify cost or lack of reimbursement as key barriers.
A survey of 595 young oncologists found that 71% are at risk of developing burnout, a syndrome characterized by emotional exhaustion and depersonalization. The study highlights the need for action to address burnout across all levels, from universities to professional societies.
A new research study reveals that many patients with advanced, incurable cancer do not receive palliative care, despite the presence of designated centres promoting integrated oncology and care. The study found significant gaps in palliative care delivery, highlighting the need for increased budget allocation.
Charlie Ma, Ph.D., a Professor and Director of Medical Physics at Fox Chase Cancer Center, has been selected as an ASTRO Fellow. He is recognized for his contributions to the field of radiation oncology, including research, education, and patient care.
The European Society of Cardiology has launched newregistries for cardiac oncology and ACS, aiming to monitor treatment practices and outcomes. The registries will provide robust data on cardiovascular disease burden and treatment in Europe.
The European Society for Medical Oncology (ESMO) recognizes the contributions of three outstanding individuals in cancer research and treatment. Carsten Bokemeyer receives the ESMO Award for his work on malignant germ cell tumours, while Peter Boyle wins the Lifetime Achievement Award for his long-standing contribution to cancer epidem...
The American Society for Radiation Oncology (ASTRO) has awarded a total of $35,500 in individual grants to 43 researchers presenting at the 2014 Annual Meeting. The awards recognize top radiation oncology research from around the world and provide insight into significant advances in technology and biology.
Seven physicians receive funding to advance radiation oncology research, including studies on cancer biology, physics, and treatment outcomes. Recipients will focus on improving radiation therapy and enhancing patient care.
ASTRO Gold Medal winners Mary K. Gospodarowicz, Leonard L. Gunderson, and Nancy J. Tarbell will receive the award for their outstanding work in research, clinical care, teaching, and service. They have made significant contributions to advancing radiation oncology, improving patient outcomes, and promoting global health.
The American Society of Clinical Oncology recognizes MD Anderson leaders Gabriel Hortobagyi, Waun Ki Hong, and John Mendelsohn for their significant contributions to cancer research. Mendelsohn is known for his discovery of the monoclonal antibody Erbitux, while Hong has made groundbreaking advances in treating head and neck cancers.
Researchers at Mount Sinai present promising findings on innovative treatments for recurrent ovarian cancer, molecular profiling of bile duct and gallbladder cancers, and adjuvant therapy for melanoma. The studies demonstrate encouraging results for patients with these rare and often fatal diseases.
Leslie L. Robison, a St. Jude Children's Research Hospital researcher, has received the Pediatric Oncology Award for his contributions to childhood cancer survivorship research. Studies funded by Robison have shown that childhood cancer survivors are at an increased risk of developing new cancers and chronic health problems.
Dr. Neal Meropol, Chief of Hematology and Oncology at Case Western Reserve University, is honored as an ASCO Fellow for his exceptional volunteer service and dedication to cancer care. He has served on the ASCO Board of Directors and various committees, contributing to the organization's mission to improve cancer care.
Dr. Beverly Lange, a retired CHOP oncologist, is honored with the ASPHO Distinguished Career Award for her groundbreaking research on pediatric leukemia. Her contributions have significantly improved treatment outcomes, increasing survival rates to over 55%.
Beaumont Children's Hospital has been awarded a $20,000 grant from CureSearch to support therapeutic clinical trials for children with cancer. The hospital believes that clinical trials are essential in helping children with cancer, and this funding will enable them to open additional studies and reach more patients.
A patient diagnosed with advanced, incurable lung cancer was found to have early stage, curable lung cancer after stopping a rare antibiotic that caused liver and lung damage. The team's findings suggest that toxicity due to the antibiotic may be mistaken for cancer spread.
The American Society for Radiation Oncology (ASTRO) has issued a new guideline detailing the use of adjuvant radiation therapy in treating endometrial cancer. The guideline recommends postoperative external beam radiation for patients with early-stage disease, and vaginal cuff brachytherapy for those at high risk of vaginal recurrence.
A recent study found that the ICD-10 transition led to significant information loss, affecting about 8 percent of Medicaid codes. Financial implications also emerged, with 39 codes accounting for 2.9 percent of total Medicaid reimbursements and 5.3 percent of UI Cancer Center billing charges.
Cancer doctors can cut costs without risk to patients by improving end-of-life care, reducing unnecessary medical imaging, and negotiating lower prices for new cancer drugs. These changes can save billions of dollars in healthcare spending while maintaining quality of life.
The new guideline aims to reduce unnecessary re-excision rates by identifying optimal margin widths that minimize ipsilateral breast tumor recurrence. Wider margin widths do not significantly lower the risk, and the choice of radiation technique should not depend on margin width.
The European Society for Medical Oncology warns that Eastern Europe lacks sufficient data, highlighting the need for a unified system. Despite this, many Western European countries are expected to have enough medical oncologists to meet growing cancer demands by 2020.
The European Society for Medical Oncology (ESMO) releases a position paper on the role of medical oncologists in cancer care, emphasizing the importance of their specialist training. The paper aims to guarantee access to optimal treatment for Europe's growing number of cancer patients.
A global survey by the European Society for Medical Oncology found that over half of the world's population lives in countries with regulations limiting access to opioid medicines for managing cancer pain. The study highlights the need for regulatory reform and education to improve access to these medicines.
A study by MU researchers discovered that older siblings' cells can be passed from a female dog to her puppies while they are still in the womb. This finding will help further investigate the health effects of microchimerism in dogs and humans.
The article discusses new recommendations for overcoming issues related to cancer clinical trial accrual. Strategies include involving patient advocates and improving communication with patients, developing evidence-based training initiatives for providers, and promoting accrual through leadership best practices at the site level.
Researchers Dr. Joan Seoane and Dr. Eduard Batlle from Barcelona have been recognized for their outstanding contributions to cancer research, with a focus on brain cancer and colorectal tumors. Their work aims to identify tumor stem cells and develop new therapeutic strategies to block metastasis.
The European Society for Medical Oncology emphasizes the need for new testing methods to ensure patients benefit from personalized cancer treatments. Researchers are working on developing new approaches to analyze tumour characteristics and select targeted therapies.
Radiation oncologists face higher workloads and decreased confidence when treating unfamiliar cases, as shown in a UNC study. The researchers used NASA-TLX to measure perceived workload and found that performance decreased with longer completion times.
A two-item questionnaire, including PHQ-9 and PHQ-2, effectively screened for depression in radiation therapy patients. The study found that these questions were as useful as the entire PHQ-9 in identifying depression, with an area under the curve of approximately 0.83.
The ASTRO/AUA joint guideline offers clinical principles and recommendations for radiation therapy use in patients with and without evidence of prostate cancer recurrence. The guideline is based on a comprehensive review of 324 research articles and provides detailed efficacy data for patients with detectable and undetectable PSA levels.
The ESMO Designated Centres programme has seen a significant increase in new applications, with 37 successful new entrants in 2013. The programme aims to promote integrated oncology and palliative care services for cancer patients and has been highly successful, with over 160 centres recognized globally.
Jean B. Owen, PhD, receives the highest honor from ASTRO for her extensive work in establishing and analyzing benchmarks for optimal care in radiation oncology. Her contributions include developing clinical performance measures and survey processes to improve quality of care nationwide.
Cora Sternberg receives the ESMO Award for her pioneering research on genitourinary cancers, while Franco Cavalli is awarded the ESMO Lifetime Achievement Award for his long-standing contribution to lymphoma research. Roger Stupp wins the Hamilton Fairley Award for his relentless research on malignant gliomas and other cancers.
The American Society for Radiation Oncology (ASTRO) has selected 10 outstanding members to receive the Fellow of ASTRO designation. These distinguished individuals have made substantial contributions to the field of radiation oncology through research, education, patient care, and leadership.
The American Society for Radiation Oncology (ASTRO) awarded a total of $34,500 to 42 researchers selected for the 2013 Annual Meeting Abstract Awards. The awards recognized outstanding abstracts in seven categories and honored top-rated research in radiation and cancer biology, clinical practice, and radiation physics.
ASTRO has awarded Amato Giaccia, Radhe Mohan, and Prabhakar Tripuraneni with the Society's highest honor—the ASTRO Gold Medal. The awardees have made outstanding contributions to radiation oncology through research, clinical care, teaching, and service.
A study found that radiation oncology received only 1.6% of the $30.9 billion in NIH-funded grants for cancer research in FY 2013. This disparity highlights an urgent need for increased funding to improve patient survival and treatment outcomes.
The new guideline provides detailed direction on treatment options for prostate cancer patients, including adjuvant and salvage radiotherapy recommendations. It emphasizes the importance of informed consent and patient education on potential side effects and benefits of radiation therapy.
A new study found that a commonly used US stem cell transplant regimen for advanced neuroblastoma in children was associated with more acute toxicity, particularly to the kidneys and liver. The study informed the recent decision of the Children's Oncology Group to switch to an equally effective European approach.
The new ASTRO white paper recommends 10 fundamental elements for safe and effective IGRT practices, including establishing a multi-professional team and performing end-to-end testing for new procedures. The paper aims to improve the safety and effectiveness of image-guided radiation therapy in radiation oncology.
A Phase III clinical trial found that adding cetuximab to chemotherapy enables previously inoperable patients to undergo surgery, tripling the rates of successful surgery for liver metastasis. The combination also extends median overall survival by 10 months compared to chemotherapy alone.
The ASTRO white paper emphasizes the vital role of patient-specific peer review in improving patient safety and quality of care. The report details suggested targets for peer review throughout various areas within radiation therapy, prioritizing those most likely to impact patient outcomes.
Pediatric oncologist Garrett Brodeur will receive the Pediatric Oncology Award and deliver a lecture highlighting his work on predicting disease course in neuroblastoma. His research has led to better understanding of the cancer's biology and development of more effective treatments.
Outpatient oncology practices have seen a significant increase in performance on quality measures, especially in adopting new clinical practices. The mean normalized performance score improved from 71 to 85 percent between 2006 and 2010.
A prospective study found that children with low-risk retinoblastoma do not need postoperative chemotherapy to prevent disease recurrence or metastasis. The results suggest that certain patients with intermediate-risk disease can receive less aggressive adjuvant treatment or even forego it altogether.
The University of Louisville's interdisciplinary curriculum for oncology palliative education (iCOPE) prepares students to work together as a team, addressing psycho-social-spiritual and physical needs. This innovative program aims to improve patient care and graduate students who demand interdisciplinary teams.
A recent study published in The Lancet Oncology reveals that patients with low-grade serous carcinoma of the ovary or peritoneum can experience tumor stabilization or shrinkage after taking a regular dose of selumetinib. This breakthrough discovery offers new possibilities for treating previously chemoresistant tumors.
A Phase I clinical trial demonstrated the therapeutic effect of RNAi gene silencing in treating advanced cancer patients. The drug, ALN-VSP, presented good evidence for clinical utility and showed significant tumor response in 11 out of 37 patients.
A recent study by Vall d'Hebron Institute of Oncology has led to the redefinition of hormone-sensitive breast tumours, improving diagnosis and treatment outcomes. Gene expression analysis revealed discrepancies between histopathological data and molecular profiles, prompting a new definition that incorporates progesterone receptor levels.
A study by TGen and US Oncology Research identified genetic mutations in 14 metastatic TNBC patients, including TP53 and ERBB4 tumor suppressor genes. The research offers potential drug targets for this aggressive form of breast cancer.
The American Society of Clinical Oncology (ASCO) has released its annual report on the top cancer advances of 2012, showcasing significant developments in precision medicine and targeted treatments. The report highlights seven new FDA approvals for anticancer agents, including therapies for breast and prostate cancers.
A series of studies by Intermountain Healthcare's Oncology Clinical Program shows that improving care across a large hospital system is possible through standardized care. Key findings include reduced mastectomies and lymph node removals in breast cancer patients, indicating a more consistent approach to treatment.